GlassScriptPhysician profile
Elizabeth Shirley
NPI 1659904761
$1,528.03
in general payments reported to CMS, 2019-2025
27 companies · $639 in 2025
The $639 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $140 · 2023: $167 · 2024: $377 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $167.97 | 2024-2025 | Daybue |
| Astrazeneca Pharmaceuticals LP | $131.34 | 2025 | Farxiga |
| Novo Nordisk INC | $117.33 | 2025 | Wegovy, Ozempic |
| Medtronic, INC. | $114.81 | 2024 | Gi Genius, Nexpowder |
| Tris Pharma INC | $113.05 | 2021-2025 | Dyanavel Xr |
| Neurelis, INC. | $98.54 | 2023-2025 | Valtoco |
| Ucb, INC. | $86.13 | 2024-2025 | Nayzilam, Briviact |
| Glaxosmithkline, LLC. | $75.29 | 2022-2023 | Pediarix |
| Exact Sciences Corporation | $63.58 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Verrica Pharmaceuticals INC. | $59.62 | 2024 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $59.58 | 2021-2022 | |
| Sanofi Pasteur INC. | $49.65 | 2021-2024 | |
| Photonicare INC | $47.96 | 2023 | Otosight Middle Ear Scope |
| Pfizer INC. | $47.68 | 2022-2025 | |
| Corium, LLC | $44.16 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $35.60 | 2023-2024 | Reblozyl |
| Smith+Nephew, INC. | $30.40 | 2025 | Collagenase Santyl |
| Adlon Therapeutics L.P. | $26.79 | 2021 | |
| Cipher Pharmaceuticals US LLC | $23.93 | 2025 | Natroba, Spinosad |
| Organon LLC | $22.99 | 2025 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $22.87 | 2024 | |
| Abbvie INC. | $21.74 | 2021 | |
| Lilly USA, LLC | $18.65 | 2025 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $17.73 | 2023 | Opdualag |
| Ironshore Pharmaceuticals INC. | $13.48 | 2023 | Jornay Pm |
| Phadia US INC. | $13.16 | 2022 | |
| Genentech USA, INC. | $4.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Shirley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.